Key result
Polymorphisms in VKORC1 and CYP2C9 genes, combined with nongenetic factors, explained 51.4% of the variability in warfarin dose requirements.
Why the study?
Do genetic polymorphisms in VKORC1, CYP2C9, and coagulation factors influence warfarin dose requirements in patients on stable therapy?
Population
350 patients receiving stable doses of warfarin at 3 consecutive visits
Design
Cross-sectional
Authors
Loading...
Supports VKORC1/CYP2C9 inclusion in dosing models; leaves open outcome benefits pending prospective trials.
Observational (n=350)
Do genetic polymorphisms in VKORC1, CYP2C9, and coagulation factors influence warfarin dose requirements in patients on stable therapy?
Polymorphisms in VKORC1, CYP2C9, and coagulation factors, along with clinical variables, explain over 50% of the variability in stable warfarin dose requirements.
Aquilante et al. (2006) conducted an observational in Patients receiving stable doses of warfarin (n=350). Genetic polymorphisms (VKORC1, CYP2C9, coagulation factors) was evaluated on Mean warfarin dose requirements. Polymorphisms in VKORC1 and CYP2C9 genes, combined with nongenetic factors, explained 51.4% of the variability in warfarin dose requirements.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: